Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
grade C 56.75 2.07% 1.15
RGEN closed up 2.07 percent on Thursday, January 17, 2019, on 68 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical RGEN trend table...

Date Alert Name Type % Chg
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 17 Up 3 Days in a Row Strength 0.00%
Jan 16 Doji - Bearish? Reversal 2.07%
Jan 16 Overbought Stochastic Strength 2.07%
Jan 15 Overbought Stochastic Strength 2.73%
Jan 14 Stochastic Sell Signal Bearish 4.88%
Jan 14 NR7 Range Contraction 4.88%
Jan 14 NR7-2 Range Contraction 4.88%
Jan 14 Overbought Stochastic Strength 4.88%

Older signals for RGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Is RGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 70.5
52 Week Low 29.56
Average Volume 492,655
200-Day Moving Average 50.7632
50-Day Moving Average 59.0326
20-Day Moving Average 52.6885
10-Day Moving Average 54.608
Average True Range 1.9861
ADX 20.74
+DI 26.1023
-DI 20.7669
Chandelier Exit (Long, 3 ATRs ) 51.3617
Chandelier Exit (Short, 3 ATRs ) 54.2183
Upper Bollinger Band 57.4868
Lower Bollinger Band 47.8902
Percent B (%b) 0.92
BandWidth 18.213842
MACD Line -0.5009
MACD Signal Line -1.3143
MACD Histogram 0.8133
Fundamentals Value
Market Cap 2.11 Billion
Num Shares 37.3 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 111.27
Price-to-Sales 12.40
Price-to-Book 6.72
PEG Ratio 2.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.86
Resistance 3 (R3) 59.70 58.51 59.34
Resistance 2 (R2) 58.51 57.72 58.59 59.16
Resistance 1 (R1) 57.63 57.23 58.07 57.79 58.99
Pivot Point 56.44 56.44 56.66 56.52 56.44
Support 1 (S1) 55.56 55.65 56.00 55.72 54.51
Support 2 (S2) 54.37 55.16 54.45 54.34
Support 3 (S3) 53.49 54.37 54.16
Support 4 (S4) 53.65